Trastuzumab Envedotin

Summary

Trastuzumab Envedotin (CHEMBL6068184) is a phase-3 clinical-stage antibody drug conjugate; indicated across 2 conditions including breast neoplasm and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody drug conjugate
• Indications: 2 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068184
Name	Trastuzumab Envedotin
Type	Antibody drug conjugate
Max phase	3

Also known as: DP-303C, Dp303c, Trastuzumab envedotin, Trastuzumab envedotina, Trastuzumab envedotine, TRASTUZUMAB ENVEDOTIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast neoplasm	3	MONDO:0021100	MONDO:0007254
neoplasm	2	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05901935	PHASE3	NOT_YET_RECRUITING	DP303c in Patients With HER2-positive Advanced Breast Cancer
NCT06313086	PHASE3	RECRUITING	DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
NCT06577376	PHASE1/PHASE2	NOT_YET_RECRUITING	A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
NCT07241936	PHASE1/PHASE2	RECRUITING	A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
NCT04826107	PHASE2	UNKNOWN	Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer
NCT04828616	PHASE2	UNKNOWN	Study of DP303c Injection in Patients With Advanced Ovarian Cancer
NCT05334810	PHASE2	UNKNOWN	DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
NCT05810103	PHASE1	UNKNOWN	A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).